Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.
1 report, 1 independent
Updated Fri 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
- Major financial institutions, including Goldman Sachs, Wells Fargo, and Citigroup, are navigating economic uncertainty driven by the war in Iran.
- Financial institutions made various moves on June 18, 2026, including TD Cowen lowering its price objective, Citigroup raising its target, and Royal Bank of Canada increasing its target price. Separately, Man Group reduced its stock holdings.
-
Leerink partners
U.S. investment bank
Related events
- Citigroup raised shares to a buy rating for Fisher & Paykel Healthcare.
- Citigroup reissued a market outperform rating for Sphere Entertainment Co. stock.
- Leerink Partners started coverage on Nautilus Biotechnology on October 6, 2026.
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- Citigroup, Jefferies, and Freedom Capital issued rating updates on an unnamed stock.